Comparing Pioglitazone and Empagliflozin for Diabetes Caused by Pancreatitis
Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial
This project compares two existing diabetes medicines, pioglitazone and empagliflozin, to see which works better for people whose diabetes is caused by pancreatitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11158887 on NIH RePORTER |
What this research studies
Diabetes linked to chronic or recurrent acute pancreatitis (CP-DM) often leads to worse health outcomes and harder-to-manage blood sugar compared to other types of diabetes. Current treatments for CP-DM are not always effective, and there haven't been many rigorous studies comparing different options. This project will directly compare two medicines, pioglitazone and empagliflozin, to understand which one might be a better choice for managing blood sugar and improving overall health for individuals with CP-DM. Pioglitazone has shown promise in animal models and in people with Type 2 Diabetes by improving insulin resistance and reducing inflammation. Empagliflozin is another established diabetes medication that will be compared.
Who could benefit from this research
Good fit: Ideal candidates for this type of research would be individuals diagnosed with diabetes specifically linked to chronic or recurrent acute pancreatitis.
Not a fit: Patients whose diabetes is not related to pancreatitis, or those with contraindications to either pioglitazone or empagliflozin, would likely not benefit from this specific trial.
Why it matters
Potential benefit: If successful, this trial could identify a more effective and safer treatment option for managing diabetes caused by pancreatitis, potentially improving quality of life and reducing complications.
How similar studies have performed: While pioglitazone and empagliflozin have shown success in treating Type 2 Diabetes, very few or no randomized controlled trials have directly compared antihyperglycemic therapies specifically for diabetes caused by pancreatitis.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kudva, Yogish C. — Mayo Clinic Rochester
- Study coordinator: Kudva, Yogish C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.